Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

August 11, 2017: By Jon Swedien

Allegro logoAllegro Ophthalmics on Aug. 9 reported positive results from its Phase IIb Stage 2 clinical trial for Luminate.

Luminate—a first-in-class integrin peptide therapy that treats neovascular retinal diseases—met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME) in the DEL MAR Stage 2 study, according to the San Juan Capistrano, California, company.

The primary endpoint was non-inferiority to bevacizumab in mean change in best-corrected visual acuity (BCVA) at 20 weeks when Luminate was used with a single bevacizumab pretreatment (sequential therapy) or in combination with bevacizumab.

The Luminate results were achieved after one treatment of 1.25 mg bevacizumab (week zero) followed by three 1 mg Luminate injections (weeks one, four, and eight) and 12 weeks off treatment, compared with five injections given every four weeks with bevacizumab.

The data showed the mean gain in BCVA was 7.1 letters for patients in the Luminate with bevacizumab pretreatment (sequential) group compared with 6.7 letters for patients in the bevacizumab control group.

The double-masked, placebo-controlled, randomized, multicenter, five-month Phase IIb, Stage 2 trial, conducted at 14 US sites, included five arms:

— Luminate 0.5 mg or 1.0 mg as a sequential therapy after a single treatment of 1.25 mg bevacizumab (week zero) followed by three Luminate injections (weeks one, four, and eight), and 12 weeks off treatment;

— Luminate 0.5 mg or 1.0 mg given in direct combination with bevacizumab 1.25 mg at weeks one, four, and eight, and 12 weeks off treatment;

— A 1.25 mg bevacizumab control arm of five monthly injections.

The trial also found that Luminate was well-tolerated with no drug toxicity or intraocular inflammation. These safety results are consistent with previously conducted Luminate studies on human subjects where there were no reports of significant inflammation and no evidence of retinal tears or detachments.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023